(Q34482141)

2 August 2017

1 reference

title

A general assessment of the safety of HMG CoA reductase inhibitors (statins). (English)

1 reference

2 August 2017

Donald M Black

1

1 reference

2 August 2017

publication date

1 January 2002

1 reference

Current Atherosclerosis Reports

2 August 2017

published in

1 reference

2 August 2017

volume

4

1 reference

2 August 2017

issue

1

1 reference

2 August 2017

page(s)

34-41

1 reference

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

2 August 2017

cites work

1 reference

12 December 2020

Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions

1 reference

12 December 2020

Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Cholesterol Treatment Trialists' (CTT) Collaboration

1 reference

12 December 2020

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

12 December 2020

The Effect of Atorvastatin on the Human Lens After 52 Weeks of Treatment

1 reference

12 December 2020

Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels

1 reference

12 December 2020

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

12 December 2020

An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor

1 reference

12 December 2020

Statin-fibrate combination therapy

1 reference

12 December 2020

Drug interactions and the statins.

1 reference

12 December 2020

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

12 December 2020

Long-term safety and efficacy profile of simvastatin

1 reference

12 December 2020

Statins in children: what do we know and what do we need to do?

1 reference

12 December 2020

High elevations of creatine phosphokinase in hypothyroidism. An isoenzyme analysis

1 reference

12 December 2020

Safety of statins (hydroxymethyl glutaryl coenzyme a reductase inhibitors): different mechanisms of metabolism and drug transport may have clinical relevance

1 reference

12 December 2020

Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study

1 reference

12 December 2020

Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase

1 reference

12 December 2020

Evaluating asymptomatic patients with abnormal liver function test results.

1 reference

12 December 2020

Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy

1 reference

12 December 2020

A survey on factors that could affect adverse drug reaction reporting according to hospital pharmacists in Great Britain

1 reference

12 December 2020

Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients.

1 reference

12 December 2020

Cholestatic jaundice associated with lovastatin (Mevacor) therapy

1 reference

12 December 2020

Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolism-monograph for physicians

1 reference

12 December 2020

Clofibrate-lnduced acute muscular syndrome

1 reference

12 December 2020

Comparative tolerability of the HMG-CoA reductase inhibitors

1 reference

12 December 2020

Clinical experience with lovastatin.

1 reference

12 December 2020

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

1 reference

12 December 2020

10.1007/S11883-002-0060-0

Identifiers

DOI

1 reference

Dimensions Publication ID

2 August 2017

1011401273

0 references

1 reference